Trials / Sponsors / ReCode Therapeutics
ReCode Therapeutics
Industry · 6 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Active Not Recruiting | Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucoci Primary Ciliary Dyskinesia (PCD) | Phase 1 | 2024-10-22 |
| Completed | A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD Primary Ciliary Dyskinesia | Phase 1 | 2024-09-20 |
| Recruiting | A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Parti Cystic Fibrosis | Phase 2 | 2024-02-01 |
| Active Not Recruiting | A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Primary Ciliary Dyskinesia | — | 2023-08-31 |
| Active Not Recruiting | A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults Primary Ciliary Dyskinesia | — | 2023-03-08 |
| Completed | Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects Primary Ciliary Dyskinesia | Phase 1 | 2023-02-18 |